Cytotoxicity News and Research

RSS

Genoscience Pharma's GNS561 shows potential against SARS-CoV-2 in vitro

A new study published on the preprint server bioRxiv in October 2020 shows that a combination of a new compound GNS561 and remdesivir act synergistically against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This suggests that autophagy inhibitors could be an alternative strategy for SARS-CoV-2 infection.

12 Oct 2020

Suramin shows promise as COVID-19 treatment

A new study published on the preprint server bioRxiv reports the elucidation of the mechanism of inhibition of SARS-CoV-2 by a non-nucleotide inhibitor called suramin. This is the first such compound to be shown to have such activity and shows promise for use as a repurposed drug against COVID-19.

12 Oct 2020

Novel radioimmunotherapy proven effective in reversing resistance to lymphoma therapy

A new radioimmunotherapy has proven effective in reversing resistance to the most commonly used lymphoma drug, rituximab, according to research published in the October issue of The Journal of Nuclear Medicine.

8 Oct 2020

Resveratrol and pterostilbene inhibit SARS-CoV-2 infection in vitro

A team of scientists at the University of Groningen, in the Netherlands, demonstrates that a natural plant product, resveratrol, and its structural analog, pterostilbene, have long-lasting antiviral effects against severe acute respiratory coronavirus 2 (SARS-CoV-2) infection. The study is currently available on the bioRxiv preprint server.

28 Sep 2020

BAT study analyzes the toxicological impact of nicotine pouch products

New research by BAT indicates that modern oral products (MOPs) showed lower toxicity responses in certain assays than traditional cigarettes.

28 Sep 2020

Anti-N-protein IgG may predict severity of COVID-19

A recent study by researchers at the University of Miami, Miami VA Healthcare System and Express Gene and published on the preprint server medRxiv in September 2020 reports on the prognostic significance of the anti-N Immunoglobulin G (IgG) antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

28 Sep 2020

Optimal antibody combinations and Fc binding inhibit SARS-CoV-2 in vivo

A recent study by researchers at the University of North Carolina at Chapel Hill and The Rockefeller University and published on the preprint server bioRxiv in September 2020 shows that a combination of neutralizing antibodies with intact Fc effector function can effectively reduce the viral load and prevent infection.

17 Sep 2020

Anti-CD73 molecule CPI-006 activates B cell responses to SARS-CoV-2

As the COVID-19 pandemic continues to cause an immense impact across many parts of the world, the role played by immune responses is becoming more evident every day. A recent funded paper published on the preprint server medRxiv* in September 2020 reports the initiation of a Phase I trial of a drug that increases antibody and cell-mediated immune responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

17 Sep 2020

Study provides insight into lymphomagenesis and patterns of resistance to immunotherapy

Lymphomas are a diverse group of cancers of the immune system, which is the body's primary defense against autoimmune disease, infections, and malignancy.

16 Sep 2020

Convalescent plasma fails to improve outcome of COVID-19 in India

A new study based in India and published on the medRxiv preprint server explores the role of convalescent plasma (CP) in the treatment of moderate COVID-19 within the limitations on resources faced in a developing country.

9 Sep 2020

ACE2/TMPRSS2 not expressed in pancreatic islet endocrine cells

A new study by researchers at the Vanderbilt University Medical Center and the University of Pennsylvania Perelman School of Medicine and published on the preprint server bioRxiv* in August 2020 reports that both key enzymes that are required for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) entry into the human host cell are lacking in the beta cells of the pancreatic islet. This rules out the direct injury hypothesis for impaired glucose control in patients with COVID-19 disease.

1 Sep 2020

Silicon nitride shows potent SARS-CoV-2 neutralization capability

A new study published on the preprint server bioRxiv* in August 2020 shows that the man-made compound silicon nitride, which is used in medical implants and high mechanical performance engineering applications, is capable of inactivating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at varying concentrations without causing cell cytotoxicity. This finding should be investigated to develop disinfectants to clear the virus from surfaces, preventing its spread.

1 Sep 2020

New lipid derivatives of Remdesivir have higher anti-coronavirus activity

In a fascinating new preprint paper published on bioRxiv* in August 2020, the researchers report “the synthesis and antiviral evaluation of three novel lipophilic prodrugs of RVn-monophosphate that are substantially more active than Remdesivir in cells infected with SARS-CoV-2.” These could be of immense use in treating COVID-19 patients early and helping to end transmission.

30 Aug 2020

Inhaled steroid ciclesonide suppresses SARS-CoV-2 replication in vitro

A new paper by researchers at Japan’s National Institute of Infectious Diseases and published on the preprint server bioRxiv in August 2020 reports the in vitro suppression of coronavirus (CoV) replication by an inhaled corticosteroid (ICS) ciclesonide.

26 Aug 2020

Whey protein from human breastmilk inhibits SARS-CoV-2 infection

Many scientists have reported the effects of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection on pregnancy and the virus has been detected in breastmilk. Now a new study published on the preprint server bioRxiv* in August 2020 shows that whey protein in human breastmilk efficiently prevents infection with SARS-CoV-2 as well as post-entry viral replication.

20 Aug 2020

DHODH inhibitor PTC299 shows potential as a COVID-19 therapeutic

As COVID-19 continues to take a heavy toll on human health and life in many parts of the world, there is still no effective antiviral drug or vaccine. This has fueled an intensive search for small molecules and proteins that can inhibit viral entry and replication.

10 Aug 2020